Pfizer selects Pristima for Drug Safety R&D data management solution
Pristima is software as a service (SaaS) model that consolidates several systems and applications into a single, global solution. As part of the deal, Pfizer will implement a
Pristima is software as a service (SaaS) model that consolidates several systems and applications into a single, global solution. As part of the deal, Pfizer will implement a
Data from two clinical trials was presented at the American Diabetes Association 74th Scientific Sessions. In the two-year trial, empagliflozin in combination with certain other diabetes therapies showed
The company said that Lymphoseek becomes the first and only FDA-approved radiopharmaceutical application for sentinel lymph node detection and was first approved in March 2013 for lymphatic mapping
As part of the deal, the option to license extended to Celgene through the end of Phase I, but AG-221 has been exercised early based on the Phase
The FDA approval is based on priority review of two, multi-center, Phase III studies GEMMA-1 and GEMMA-2 carried out in 13 countries. The GEMMA principal investigator Gillian Newsteads
As part of the deal, Veristat will provide strategic statistical consulting and biometrics services, including study design, statistical analysis and data presentation, for a number of new cancer
In February 2013, both the firms have voluntarily recalled all lots of Omontys and suspended promotional activities in the US after postmarketing reports of serious hypersensitivity reactions including
About 93 subjects at 38 centres in 14 countries were enrolled in PETIT2, a 2-part, double-blind, randomised placebo-controlled and open-label trial, which was designed to investigate the efficacy,
The tablets, a combination of 100mg aspirin and 15mg lansoprazole, are the first FDC drug in Japan to combine low-dose aspirin with a proton pump inhibitor. The company
Rilpivirine is a non-nucleoside reverse transcriptase inhibitor and is currently being marketed as Edurant, while dolutegravir is an integrase inhibitor marketed as Tivicay. If successfully developed and approved